Drug class
BCMA-directed antibody–drug conjugate (ADC); antineoplastic biologic
Mechanism of action
The antibody binds B-cell maturation antigen (BCMA) on myeloma cells and is internalised. Intracellular release of the microtubule-disrupting payload monomethyl auristatin F (MMAF) inhibits tubulin polymerisation, causes cell-cycle arrest and induces apoptosis; antibody-dependent cellular cytotoxicity may also contribute.
General use cases
- In combination with bortezomib and dexamethasone for adults with relapsed or refractory multiple myeloma who have received at least two prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent, under the US FDA approval of 23 Oct 2025
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
